Söderlin M K, Geborek P
Spenshult Rheumatology Hospital, Oskarström, Sweden.
Ann Rheum Dis. 2008 Jan;67(1):37-42. doi: 10.1136/ard.2007.070714.
To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patients in southern Sweden, a region with no formal or economic restrictions for the use of biological treatment in rheumatological diseases. Specifically, we studied conformity with the national Swedish guidelines for biologics in RA.
Rheumatologists in southern Sweden contribute to a voluntary register on the use of biologics in treating arthritis patients (the South Swedish Arthritis Treatment Group (SSATG)). This register covers .90% of all the prescriptions of biologics for arthritis patients in the region. The treatment of 1839 patients (2704 treatment occasions) was recorded in the SSATG register during 1999-2006. Baseline characteristics were analysed.
Baseline Health Assessment Questionnaire(HAQ) scores and Disease Activity Scores (DASs)decreased significantly between 1999 and 2006, but disease activity remained high in RA patients. RA patients were treated with biologics earlier, but only 16% of the patients received biologics within 2 years of disease onset in 2006. The percentage of RA patients who were prescribed biologics after only one previous non-biological DMARD (disease-modifying anti-inflammatory rheumatic drug) was 27% in 2006. Thirty-five per cent of all RA patients changed from one biological treatment to another.
Baseline DASs in RA patients remained high at the start of biological treatment. The national Swedish guidelines for the prescription of biologics in RA were followed. More patients with early RA were treated with biologics. The proportion of RA patients changing from one biological drug to another increased.
研究瑞典南部类风湿关节炎(RA)患者生物治疗的处方模式,该地区在风湿性疾病生物治疗的使用上没有形式或经济限制。具体而言,我们研究了瑞典全国RA生物制剂指南的遵循情况。
瑞典南部的风湿病学家向一个关于生物制剂用于治疗关节炎患者的自愿登记册(瑞典南部关节炎治疗组(SSATG))提供数据。该登记册涵盖了该地区关节炎患者生物制剂所有处方的90%以上。1999年至2006年期间,SSATG登记册记录了1839例患者(2704个治疗疗程)的治疗情况。分析了基线特征。
1999年至2006年间,健康评估问卷(HAQ)基线评分和疾病活动评分(DAS)显著下降,但RA患者的疾病活动度仍然较高。RA患者开始生物治疗的时间较早,但2006年只有16%的患者在疾病发作2年内接受了生物治疗。2006年,仅在使用过一种非生物性改善病情抗风湿药物(DMARD)后就接受生物制剂治疗的RA患者比例为27%。所有RA患者中有35%从一种生物治疗转换为另一种生物治疗。
RA患者生物治疗开始时的基线DAS仍然较高。遵循了瑞典全国RA生物制剂处方指南。更多早期RA患者接受了生物治疗。从一种生物药物转换为另一种生物药物的RA患者比例增加。